EGFR and non-small cell lung carcinoma: This study has identified a set of symptomatic AEs and disease symptoms and impacts associated specifically with a patient population identified to have NSCLC with EGFR Exon 20ins and establishes one of the first baseline assessments as to our understanding of this emerging patient population.